Translational Endocrinology & Metabolism: Breast Cancer
Translational Endocrinology & Metabolism: Breast Cancer
A comprehensive review of current knowledge of the hormonal regulation of the breast and its clinical consequences, following the translational path from basic information to clinical application.
March 2012, Guest Editor: Richard J. Santen
This continuing medical education activity should be of substantial interest to endocrinologists, oncologists, and other physicians and allied healthcare providers treating patients with breast cancer.
Upon completion of this educational activity, learners will be able to:
- Recognize the importance of reproductive and hormonal factors as they relate to risk of breast cancer;
- Discuss the mechanisms whereby estrogens initiate and promote breast cancer development;
- Describe the physiological and pathophysiological mechanisms regulating estrogen formation and action in the postmenopausal breast;
- Discuss the biological pathways through which estrogen and progesterone act in the human breast;
- Describe the different effects progestogens may have on the human breast;
- Inform patients about genetic and environmental factors that may affect the risk for development of breast cancer;
- Differentiate between absolute and relative risk, and communicate absolute, not relative risk, for increased likelihood of breast cancer diagnosis resulting from hormone therapy;
- Evaluate existing and emerging strategies for preventive interventions and treatment of breast cancer;
- Review the pharmacology, pharmacogenomics and clinical uses of SERMs and aromatase inhibitors in adjuvant therapy and prevention of breast cancer;
- Recognize the side-effects of SERMs and aromatase inhibitors;
- Discuss current theories explaining breast cancer resistance to the selective estrogen receptor modulator, tamoxifen.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of Editor-in-Chief, Dr. Paul Robertson, and Guest Editor, Dr. Richard J. Santen.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: Henry Burger, M.D., served as chair for Pfizer Australia’s Women’s Health Advisory Board and was a speaker for Novo-Nordisk; Richard Santen, M.D., has served as an advisory board member for Novo Nordisk, Pfizer, and Teva; Carolyn Smith, Ph.D., has served as a principal investigator and speaker for Pfizer.
The following faculty reported no relevant financial relationships: Kristy A. Brown, Ph.D.; Christine Clarke, Ph.D.; Renee Turzanski Fortner, Ph.D.; Matthew Goetz, M.D.; J. Dinny Graham, Ph.D.; Susan Hankinson, Sc.D.; Heidi N. Hilton, Ph.D.; James Ingle, M.D.; Evan Simpson, Ph.D.; Saad J. Sirop, M.D.; James Yager, Ph.D.
Editor-in-Chief, Paul Robertson, M.D., who planned and reviewed content for this activity, reported no relevant financial relationships.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grants.
- 8.00 AMA PRA Category 1 Credits™
- 8.00 CME Certificate of Participation